Lanreotide Sun (Lanreotide)

Lanreotide mimics the natural hormone somatostatin and binds to somatostatin receptors 2 and 5 on target cells. This binding activates inhibitory signaling pathways that lower cyclic AMP and calcium influx, leading to reduced secretion of growth hormone, insulin, glucagon, and other peptide hormones.

The dosage and administration schedule for Lanreotide Sun are determined by the prescribing clinician based on the patient’s condition, disease severity, and response to therapy. The prescriber will select the appropriate dose and injection interval.

Safety of Lanreotide Sun in pregnancy has not been established, and it should be used only if the potential benefit justifies any potential risk to the fetus. Limited data are available for breastfeeding; therefore, caution is advised and a risk‑benefit assessment should be performed.

To request Lanreotide Sun, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if required) and import documentation.

The primary alternative in the same class is octreotide, another somatostatin analog. Both agents suppress hormone secretion, but Lanreotide has a longer dosing interval (often every 4‑8 weeks) compared with octreotide, which may require more frequent injections. Choice depends on clinical response, convenience, and physician preference.

Lanreotide Sun should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Do not freeze the product. Before use, inspect the vial for particulate matter and ensure the solution is clear.

Lanreotide Sun is given by subcutaneous injection, typically using a pre‑filled syringe or autoinjector. The injection site is usually the abdomen or thigh. The prescribing clinician determines the injection frequency, which may range from monthly to every two months depending on the therapeutic indication.

Serious adverse events include gallbladder disease such as cholelithiasis, pancreatitis, severe hyperglycemia that may lead to diabetic ketoacidosis, allergic reactions including anaphylaxis, and cardiac arrhythmias. Patients should be monitored for abdominal pain, elevated blood glucose, and any signs of hypersensitivity.

Lanreotide Sun is contraindicated in patients with known hypersensitivity to lanreotide or any of its excipients. Caution is advised in individuals with severe hepatic impairment, uncontrolled diabetes, or active gallbladder disease. Pregnant women should only use it when the potential benefit outweighs the risk.